Korean J Med.  2016 Jan;90(1):7-14. 10.3904/kjm.2016.90.1.7.

Chemotherapy and Targeted Therapy beyond Adenocarcinoma of the Lung: Neuroendocrine Carcinoma

Affiliations
  • 1Division of Hematology-Oncology, Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea. Kwonjhye@naver.com

Abstract

Neuroendocrine carcinoma (NEC) has been reported to comprise 25% of lung cancer cases. NEC is classified as typical carcinoid, atypical carcinoid, large-cell neuroendocrine carcinoma, and small-cell lung cancer. Carcinoid tumors are less aggressive and surgery is the mainstay of treatment; however, patients with metastatic or inoperable disease need systemic therapy to control carcinoid symptoms and improve survival. Somatostain analogues, targeted agents including everolimus, sunitinib, bevacizumab, and conventional chemotherapy have emerged as treatment options for such patients. Large-cell neuroendocrine carcinoma exhibits more aggressive behavior and has a poorer prognosis than carcinoid tumors. No standard adjuvant and palliative chemotherapeutic agents have yet been established. This review sets out the treatment options for neuroendocrine tumors.

Keyword

Neuroendocrine tumors; Carcinoid tumor; Lung neoplasms

MeSH Terms

Adenocarcinoma*
Carcinoid Tumor
Carcinoma, Neuroendocrine*
Drug Therapy*
Humans
Lung Neoplasms
Lung*
Neuroendocrine Tumors
Prognosis
Bevacizumab
Everolimus
Full Text Links
  • KJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr